/
DCTH
$12.95+$0.01 (+0.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$446.7M
35M shares
52-week range
$8.12 – $13.72
86% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $1.6M | $1.6M | $3.6M | $2.7M | $2.1M | $37.2M | $85.2M |
| Cost of revenue | $1.0M | $719.0K | $640.0K | $671.0K | $686.0K | $635.0K | $6.2M | $11.8M |
| Gross profit | $2.4M | $861.0K | $1.0M | $2.9M | $2.0M | $1.4M | $31.0M | $73.4M |
| Gross margin | 70.4% | 54.5% | 61.1% | 81.1% | 74.8% | 69.2% | 83.4% | 86.2% |
| R&D | $19.6M | $9.5M | $11.2M | $13.8M | $18.6M | $17.5M | $13.9M | $29.2M |
| Operating income | −$27.1M | −$19.9M | −$21.3M | −$24.5M | −$33.9M | −$38.2M | −$12.4M | $660.0K |
| EBITDA | −$10.8M | −$3.9M | −$23.8M | −$24.3M | −$33.7M | −$45.8M | −$26.2M | $3.9M |
| Net income | −$19.2M | −$8.9M | −$24.2M | −$25.6M | −$36.5M | −$47.7M | −$26.4M | $2.7M |
| Net margin | -564.2% | -562.0% | -1467.6% | -721.5% | -1342.7% | -2308.9% | -70.9% | 3.2% |
| EPS (diluted) | -503.85 | -342.82 | -8.35 | -3.59 | -4.12 | -2.94 | -0.93 | 0.07 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $103M | $-0.56 | $-0.57–$-0.55 | 3 |
| 2027 | $131M | $-0.53 | $-0.55–$-0.52 | 3 |
| 2028 | $156M | $-0.14 | $-0.45–$0.17 | 5 |
| 2029 | $181M | $0.35 | $0.34–$0.35 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Delcath Systems Inc
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
www.delcath.com- Employees
- 156
- IPO / List date
- Oct 19, 2000
- HQ
- QUEENSBURY, NY
Held by traders on TradeandTell
No one on the platform currently holds DCTH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 155,300 | $1.4M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-12-24 | 1-for-700reverse |
| 2018-05-02 | 1-for-500reverse |
| 2017-11-06 | 1-for-350reverse |
| 2016-07-21 | 1-for-16reverse |
| 2014-04-09 | 1-for-16reverse |
Recent trades on TradeandTell
No one on the platform has traded DCTH yet.
